A Real-world Study Evaluating the Clinical Factors Associated with the Initial SGLT2 Inhibitor Prescription.

IF 1.2 4区医学 Q4 HEALTH POLICY & SERVICES

Journal of Health Care for the Poor and Underserved Pub Date : 2024-01-01

Michelle Chu, Mimi Lou, Mengxi Wang, Allison Flores

{"title":"A Real-world Study Evaluating the Clinical Factors Associated with the Initial SGLT2 Inhibitor Prescription.","authors":"Michelle Chu, Mimi Lou, Mengxi Wang, Allison Flores","doi":"","DOIUrl":null,"url":null,"abstract":"The American Diabetes Association (ADA) guidelines prioritize Sodicum-glucose transporter-2-inhibitors (SGLT2i) given cardio-renal and glycemic benefits. This study was conducted to observe clinical factors associated with initial SGLT2i prescription in type 2 diabetes patients eligible for SGLT2i by the ADA.Methods: A retrospective case-control study was performed in a safety-net clinic and consisted of the initial SGLT2i prescriptions group and the group without. The data from the electronic medical records between July 2021 and December 2022 were analyzed in the regressional models.Results: There was a significant association between A1c ≥8% (OR 3.7, p=.01), heart failure (OR 19.3, p<.0001), a history of hypotension (OR 11.9, p=.01), and sulfonylureas (OR 6.5, p=.003) with the SGLT2i prescription.Conclusion: Patients with high A1c levels, heart failure, a history of hypotension, and sulfonylureas were more likely than their counterparts to receive SGLT2i prescriptions. Future research should investigate adherence and provider prescribing behaviors related to SGLT2i to further assess optimal drug use.","PeriodicalId":48101,"journal":{"name":"Journal of Health Care for the Poor and Underserved","volume":"35 3","pages":"866-879"},"PeriodicalIF":1.2000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Health Care for the Poor and Underserved","FirstCategoryId":"3","ListUrlMain":"","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"HEALTH POLICY & SERVICES","Score":null,"Total":0}

引用次数: 0

Abstract

The American Diabetes Association (ADA) guidelines prioritize Sodicum-glucose transporter-2-inhibitors (SGLT2i) given cardio-renal and glycemic benefits. This study was conducted to observe clinical factors associated with initial SGLT2i prescription in type 2 diabetes patients eligible for SGLT2i by the ADA.

Methods: A retrospective case-control study was performed in a safety-net clinic and consisted of the initial SGLT2i prescriptions group and the group without. The data from the electronic medical records between July 2021 and December 2022 were analyzed in the regressional models.

Results: There was a significant association between A1c ≥8% (OR 3.7, p=.01), heart failure (OR 19.3, p<.0001), a history of hypotension (OR 11.9, p=.01), and sulfonylureas (OR 6.5, p=.003) with the SGLT2i prescription.

Conclusion: Patients with high A1c levels, heart failure, a history of hypotension, and sulfonylureas were more likely than their counterparts to receive SGLT2i prescriptions. Future research should investigate adherence and provider prescribing behaviors related to SGLT2i to further assess optimal drug use.

本刊更多论文

一项评估与 SGLT2 抑制剂首次处方相关的临床因素的真实世界研究。

鉴于钠葡萄糖转运体-2抑制剂（SGLT2i）对心血管和血糖的益处，美国糖尿病协会（ADA）指南优先考虑钠葡萄糖转运体-2抑制剂。本研究旨在观察符合 ADA 规定的 SGLT2i 首次处方条件的 2 型糖尿病患者的相关临床因素：方法：在一家安全网诊所进行了一项回顾性病例对照研究，包括首次使用 SGLT2i 处方组和未使用 SGLT2i 处方组。在回归模型中分析了2021年7月至2022年12月期间的电子病历数据：A1c≥8%（OR 3.7，p=.01）、心力衰竭（OR 19.3，p<.0001）、低血压病史（OR 11.9，p=.01）和磺脲类药物（OR 6.5，p=.003）与SGLT2i处方之间存在明显关联：结论：A1c 水平高、心力衰竭、有低血压病史和使用磺脲类药物的患者比其他患者更有可能获得 SGLT2i 处方。未来的研究应调查与 SGLT2i 相关的依从性和医疗服务提供者的处方行为，以进一步评估药物的最佳使用情况。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Health Care for the Poor and Underserved Multiple-

CiteScore

2.00

自引率

7.10%

发文量

154

期刊介绍： The journal has as its goal the dissemination of information on the health of, and health care for, low income and other medically underserved communities to health care practitioners, policy makers, and community leaders who are in a position to effect meaningful change. Issues dealt with include access to, quality of, and cost of health care.